Finance
Medical
Sports

Organogenesis

$6.97
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.02 (-0.29%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Organogenesis and other stocks, options, ETFs, and crypto commission-free!

About

Organogenesis Holdings Inc. Class A Common Stock, also called Organogenesis, is a regenerative medical company. Read More It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

Employees
700
Headquarters
Canton, Massachusetts
Founded
1985
Market Cap
636.47M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
79.04K
High Today
$7.17
Low Today
$6.77
Open Price
$6.95
Volume
18.77K
52 Week High
$310.90
52 Week Low
$6.28

Collections

Finance
Medical
Sports
Health
Entertainment
2016 IPO
US
North America

News

Yahoo FinanceMay 10

Organogenesis Holdings Inc. Reports First Quarter 2019 Financial Results

CANTON, Mass., May 10, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for its first quarter ended March 31, 2019. First Quarter 2019 Financial Summary : Net revenue of $57.1 million for the first quarter of 2019, up 60.8% compared to net revenue of $35.5 million for the ...

700

Earnings

Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Available May 10, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.